Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 1, 2016HaematologicaOpen Access

The impact of anemia on overall survival in patients with myelofibrosis treated with ruxolitinib in the COMFORT studies

View Full Paper
Ask AI
Bookmark
Share

Authors

VGVikas GuptaSher-e-Kashmir University of Agricultural Sciences and Technology of JammuCHClaire HarrisonNational Health ServiceEHElizabeth O. HexnerUniversity of Pennsylvania

Discussion

Loading...

Member takes

Implication

Randomized trial assesses anemia's role in overall survival for myelofibrosis patients treated with ruxolitinib, indicating crucial treatment considerations.

Key Points

  • This research aims to investigate the effect of anemia on overall survival in myelofibrosis patients receiving ruxolitinib treatment.
  • Analyzed survival data from COMFORT studies
  • Included myelofibrosis patients treated with ruxolitinib
  • Evaluated overall survival rates in relation to anemia status
  • Anemia significantly affected overall survival in ruxolitinib-treated patients
  • Patients with anemia had lower survival rates compared to those without anemia
  • Statistical significance indicating the need for supportive care in anemic patients

Cite This Study

Gupta et al. (2016) studied this question.

synapsesocial.com/papers/6a5fb8a393a99557d97e98b4https://doi.org/10.3324/haematol.2016.151449
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Management of cytopenias in patients with myelofibrosis treated with ruxolitinib and effect of dose modifications on efficacy outcomes2013 · 65 citations
  2. 2A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis2012 · 2,111 citations
  3. 3Impact of ruxolitinib treatment on the hemoglobin dynamics and the negative prognosis of anemia in patients with myelofibrosis2016 · 41 citations
  4. 4Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I2013 · 169 citations
  5. 5New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment2008 · 1,260 citations